Agile concludes patient recruitment in contraceptive patch Phase 3 study
The company has recruited around 1500 women two months ahead of schedule at over 100 sites throughout the US. Following the completion of the the patient recruitment, Agile
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.